131 related articles for article (PubMed ID: 20210687)
1. Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens.
Comstock TL; Holland EJ
Expert Opin Pharmacother; 2010 Apr; 11(5):843-52. PubMed ID: 20210687
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis.
White EM; Macy JI; Bateman KM; Comstock TL
Curr Med Res Opin; 2008 Jan; 24(1):287-96. PubMed ID: 18062846
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
Sheppard JD; Comstock TL; Cavet ME
Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
[TBL] [Abstract][Full Text] [Related]
5. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
[TBL] [Abstract][Full Text] [Related]
6. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.
Chen M; Gong L; Sun X; Gu Y; He X; Qu J; Wang L; Zhang M; Zhong X
Curr Med Res Opin; 2012 Mar; 28(3):385-94. PubMed ID: 22256909
[TBL] [Abstract][Full Text] [Related]
8. Treatment of ocular inflammatory conditions with loteprednol etabonate.
Pavesio CE; Decory HH
Br J Ophthalmol; 2008 Apr; 92(4):455-9. PubMed ID: 18245274
[TBL] [Abstract][Full Text] [Related]
9. Management of seasonal allergic conjunctivitis: guide to therapy.
Bielory BP; O'Brien TP; Bielory L
Acta Ophthalmol; 2012 Aug; 90(5):399-407. PubMed ID: 22067457
[TBL] [Abstract][Full Text] [Related]
10. Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis.
Mah FS; Karpecki PM
Ophthalmol Ther; 2021 Dec; 10(4):859-875. PubMed ID: 34708391
[TBL] [Abstract][Full Text] [Related]
11. Loteprednol etabonate: a review of ophthalmic clinical studies.
Howes JF
Pharmazie; 2000 Mar; 55(3):178-83. PubMed ID: 10756536
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis.
Rhee SS; Mah FS
Adv Ther; 2007; 24(1):60-7. PubMed ID: 17526462
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
[TBL] [Abstract][Full Text] [Related]
14. Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis.
Comstock TL; DeCory HH
Ocul Immunol Inflamm; 2017 Apr; 25(2):267-274. PubMed ID: 26788833
[TBL] [Abstract][Full Text] [Related]
15. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid.
Comstock TL; Sheppard JD
Expert Opin Pharmacother; 2018 Mar; 19(4):337-353. PubMed ID: 29430976
[TBL] [Abstract][Full Text] [Related]
16. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
Asbell P; Howes J
CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
[TBL] [Abstract][Full Text] [Related]
17. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.
Comstock TL; Decory HH
Int J Inflam; 2012; 2012():789623. PubMed ID: 22536546
[TBL] [Abstract][Full Text] [Related]
18. Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report.
Lu E; Fujimoto LT; Vejabul PA; Jew RL
Optometry; 2011 Jul; 82(7):413-20. PubMed ID: 21543264
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
Rajpal RK; Roel L; Siou-Mermet R; Erb T
J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
